کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2895434 1172886 2014 13 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia
ترجمه فارسی عنوان
تجربه بالینی درمان لومیتاپید در بیماران مبتلا به هیپوکلسترولمی فامیلی هموزیگوت
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
چکیده انگلیسی

The microsomal triglyceride transfer protein (MTP) inhibitor lomitapide is a licenced adjunct to a low-fat diet and other lipid-lowering medication, with or without low-density lipoprotein apheresis, for the treatment of adults with homozygous familial hypercholesterolaemia (HoFH). In a recently published phase 3 study, patients with HoFH received lomitapide in addition to maximally tolerated lipid-lowering therapy. Treatment with lomitapide resulted in a mean approximate 50% reduction in LDL-C levels after 26 weeks compared with baseline levels (p < 0.0001). This decrease in LDL-C was maintained at Weeks 56 and 78 (44% [p < 0.0001] and 38% [p = 0.0001], respectively). This paper offers clinical perspectives based on selected case histories of patients participating in the phase 3 lomitapide study. These cases provide illustrative examples of the efficacy of lomitapide, with or without apheresis, and show that the effective management of adverse effects can enable patients to remain on effective treatment.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Atherosclerosis Supplements - Volume 15, Issue 2, September 2014, Pages 33–45
نویسندگان
, , ,